CD39
Exo-nucleotidase
CD39 is a key enzyme in removing ATP from the tumor microenvironment; increased ATP may enhance the adaptive immune response against tumors.1
Additional undisclosed targets.
HIF-2π Inhibitor
Transcription factor
HIF-2Ξ± is a master transcriptional regulator of multiple genes involved in tumor progression.2
AXL Inhibitor
Tyrosine kinase
AXL overexpression is associated with tumor resistance to chemotherapy and immunotherapy drugs.3
Additional undisclosed targets.
HIF-2π, hypoxia-inducible factor 2-alpha
References: 1. Moesta et al. Targeting CD39 in Cancer. Nature Reviews Immunology volume 20, pages739β755 (2020). 2. Murugesan T, Rajajeyabalachandran G, Kumar S, Nagaraju S, Kumar S. Targeting HIF-2Ξ± as therapy for advanced cancers. Drug Discov Today. 2018;23(7):1444-1451. 3. Axelrod HD, Valkenburg KC, Amend SR, et al. AXL is a putative tumor suppressor and dormancy regulator in prostate cancer. Mol Cancer Res. 2019;17(2):356-369.
